New Pediatric Antiretroviral Agents

Journal of Pediatric Health Care

Volumn 14, Issue 4, 2000, Pages 183-190

  Collura, Jennifer M ^a   Kraus, Donna M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHILD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; NURSING; NURSING EDUCATION; PEDIATRIC NURSING; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; EDUCATION, NURSING, CONTINUING; HUMANS; PEDIATRIC NURSING;

EID: 0347741377     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0891-5245(00)27765-1     Document Type: Article

References (13)

1. Adkins, J. C., & Faulds, D. (1998). Amprenavir. Drugs, 55, 837-842.
2. Foster, R. H., & Faulds, D. (1998). Abacavir. Drugs, 55, 729-736.
3. Hughes, W., McDowell, J. A., Shenep, J., Flynn, P., Kline, M. W., Yogev, R., Symonds, W., Lou, Y., & Hetherington, S. (1999). Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrobial Agents and Chemotherapy,43, 609-615.
4. Kline, M. W., Blanchard, S., Fletcher, C. V., Shenep, J. L., McKinney, R. E., Brundage, R. C., Culnane, M., Van Dyke, R. B., Dankner, W. M., Kovacs, A., McDowell, J. A., & Hetherington, S. (1999). A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. Pediatrics [On-line], 103. Available: http://www.pediatrics.org/cgi/ content/full/103/4/e47.
5. Piscitelli, S. C., Burnstein, A. H., Chaitt, D., Alfaro, R. M., & Falloon, J. (2000). Indinavir concentrations and St. John's wort. Lancet, 355, 547-548.
6. Product Information. (1999). Amprenavir. Research Triangle Park, NC: Glaxo Wellcome Inc.
7. Product Information. (2000). Abacavir. Research Triangle Park, NC: Glaxo Wellcome Inc.
8. Product Information. (2000a). Efavirenz. Wilmington, DE: DuPont Pharmaceuticals Company.
9. Rubin, M. (2000). Important drug warning. Letter regarding potential safety concerns with the large amount of propylene glycol in Agenerase [amprenavir] oral solution. Research Triangle Park, NC: Glaxo Wellcome, Inc.
10. Starr, S. E., Fletcher, C. V., Spector, S. A., Yong, F. H., Fenton, T., Brundage, R. C., Manion, D., Ruiz, N. M., Gersten, M., Becker, M., McNamara, J., Mofenson, L. M., Purdue, L., Siminski, S., Graham, B., Kornhauser, D. M., Fiske, W., Vincent, C., Lischner, H. W., Dankner, W. M., & Flynn, P. M. (1999). Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. New England Journal of Medicine, 341, 1874-1881.
11. Taketomo, C. K., Hodding, J. H., & Kraus, D. M. (1999). Pediatric Dosage Handbook (6th ed.). Hudson, OH: Lexi-Comp, Inc.
12. Temesgen, Z., & Wright, A. J. (1999). Antiretrovirals. Mayo Clinic Proceedings, 74, 1284-1301.
13. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (2000, January 7). Guidelines for the use of antiretroviral agents in pediatric HIV infection [On-line]. Available: http://www.hivatis.org.